The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism

Gian Paolo Rossi, Valeria Bisogni, Alessandra Violet Bacca, Anna Belfiore, Maurizio Cesari, Antonio Concistrè, Rita Del Pinto, Bruno Fabris, Francesco Fallo, Cristiano Fava, Claudio Ferri, Gilberta Giacchetti, Guido Grassi, Claudio Letizia, Mauro Maccario, Francesca Mallamaci, Giuseppe Maiolino, Dario Manfellotto, Pietro Minuz, Silvia Monticone, Alberto Morganti, Maria Lorenza Muiesan, Paolo Mulatero, Aurelio Negro, Gianfranco Parati, Martino F Pengo, Luigi Petramala, Francesca Pizzolo, Damiano Rizzoni, Giacomo Rossitto, Franco Veglio, Teresa Maria Seccia, Gian Paolo Rossi, Valeria Bisogni, Alessandra Violet Bacca, Anna Belfiore, Maurizio Cesari, Antonio Concistrè, Rita Del Pinto, Bruno Fabris, Francesco Fallo, Cristiano Fava, Claudio Ferri, Gilberta Giacchetti, Guido Grassi, Claudio Letizia, Mauro Maccario, Francesca Mallamaci, Giuseppe Maiolino, Dario Manfellotto, Pietro Minuz, Silvia Monticone, Alberto Morganti, Maria Lorenza Muiesan, Paolo Mulatero, Aurelio Negro, Gianfranco Parati, Martino F Pengo, Luigi Petramala, Francesca Pizzolo, Damiano Rizzoni, Giacomo Rossitto, Franco Veglio, Teresa Maria Seccia

Abstract

Background and aim: Considering the amount of novel knowledge generated in the last five years, a team of experienced hypertensionlogists was assembled to furnish updated clinical practice guidelines for the management of primary aldosteronism.

Methods: To identify the most relevant studies, the authors utilized a systematic literature review in international databases by applying the PICO strategy, and then they were required to make use of only those meeting predefined quality criteria. For studies of diagnostic tests, only those that fulfilled the Standards for Reporting of Diagnostic Accuracy recommendations were considered.

Results: Each section was jointly prepared by at least two co-authors, who provided Class of Recommendation and Level of Evidence following the American Heart Association methodology. The guidelines were sponsored by the Italian Society of Arterial Hypertension and underwent two rounds of revision, eventually reexamined by an External Committee. They were presented and thoroughly discussed in two face-to-face meetings with all co-authors and then presented on occasion of the 36th Italian Society of Arterial Hypertension meeting in order to gather further feedbacks by all members. The text amended according to these feedbacks was subjected to a further peer review.

Conclusions: After this process, substantial updated information was generated, which could simplify the diagnosis of primary aldosteronism and assist practicing physicians in optimizing treatment and follow-up of patients with one of the most common curable causes of arterial hypertension.

Keywords: Diagnosis; Guidelines; Hypertension; Primary aldosteronism; Treatment.

Conflict of interest statement

None.

© 2020 The Authors.

Figures

Fig. 1
Fig. 1
Main steps followed in the preparation of the Guidelines.

References

    1. Funder J.W., Carey R.M., Mantero F. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2016;101:1889–1916.
    1. Carey R.M., Whelton P.K. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American college of cardiology/American heart association hypertension guideline. Ann. Intern. Med. 2018;168:351–358.
    1. da Costa Santos C.M., de Mattos Pimenta C.A., Nobre M.R. The PICO strategy for the research question construction and evidence search. Rev. Lat. Am. Enfermagem. 2007;15:508–511.
    1. Halperin J.L., Levine G.N., Al-Khatib S.M. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 2016;67:1572–1574.
    1. Bossuyt P.M., Reitsma J.B., Bruns D.E., for the STARD Group Stard 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527.
    1. McAreavey D., Murray G.D., Lever A.F., Robertson J.I. Similarity of idiopathic aldosteronism and essential hypertension. A statistical comparison, Hypertension. 1983;5:116–121.
    1. Seccia T.M., Caroccia B., Gomez-Sanchez E.P. The biology of normal zona glomerulosa and aldosterone-producing adenoma: pathological implications. Endocr. Rev. 2018;39:1029–1056.
    1. Pallauf A., Schirpenbach C., Zwermann O. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. Horm. Metab. Res. 2012;44:215–220.
    1. Rossi G.P., Bernini G., Caliumi C. For the PAPY Study Investigators, A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 2006;48:2293–2300.
    1. Lenzini L., Prisco S., Caroccia B., Rossi G.P. Saga of familial hyperaldosteronism: yet a new channel. Hypertension. 2018;71:1010–1014.
    1. Mulatero P., Tizzani D., Viola A. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms) Hypertension. 2011;58:797–803.
    1. Scholl U.I., Goh G., Stölting G. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat. Genet. 2013;45:1050–1054.
    1. Monticone S., Burrello J., Tizzani D. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 2017;69:1811–1820.
    1. Olivieri O., Ciacciarelli A., Signorelli D. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J. Clin. Endocrinol. Metab. 2004;89:4221–4226. 03-032179.
    1. Douma S., Petidis K., Doumas M. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371:1921–1926.
    1. Mantero F., Terzolo M., Arnaldi G. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J. Clin. Endocrinol. Metab. 2000;85:637–644.
    1. Baguet J.-P., Steichen O., Mounier-Vehier C., Gosse P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: epidemiology of PA, who should be screened for sporadic PA? Ann. Endocrinol. 2016;77:187–191.
    1. Mulatero P., Monticone S., Burrello J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J. Hypertens. 2016;34:2253–2257.
    1. Baudrand R., Guarda F.J., Fardella C. Continuum of renin-independent aldosteronism in normotension. Hypertension. 2017;69:950–956.
    1. Maiolino G., Calò L.A., Rossi G.P. The time has come for systematic screening for primary aldosteronism in all hypertensives. J. Am. Coll. Cardiol. 2017;69:1821–1823.
    1. Rossi G.P., Cesari M., Cuspidi C. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62–69.
    1. Mulatero P., Stowasser M., Loh K.C. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab. 2004;89:1045–1050.
    1. Tu W., Eckert G.J., Hannon T.S. Renin-angiotensin-aldosterone system racial differences in sensitivity of blood pressure to aldosterone. Hypertension. 2014;63:1212–1218.
    1. Hiramatsu K., Yamada T., Yukimura Y. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med. 1981;141:1589–1593.
    1. Loh K.C., Koay E.S., Khaw M.C. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 2000;85:2854–2859.
    1. Rossi G.P., Seccia T.M., Palumbo G. Primary Aldosteronism in the Prevalence in hYpertension (PAPY) Study Investigators, Within-patient reproducibility of the aldosterone:renin ratio in primary aldosteronism. Hypertension. 2010;55:83–89.
    1. Rossi G.P., Ceolotto G., Rossitto G. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin. Chem. Lab. Med. 2016;54:1441–1450.
    1. Gordon R.D., Wolfe L.K., Island D.P., Liddle G.W. A diurnal rhythm in plasma renin activity in man. J. Clin. Invest. 1966;45:1587–1592.
    1. Ahmed A.H., Gordon R.D., Taylor P.J. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J. Clin. Endocrinol. Metab. 2011;96:E340–E346.
    1. Stowasser M., Gordon R.D. The aldosterone-renin ratio and primary aldosteronism. Mayo Clin. Proc. 2002;77:202–203.
    1. Pizzolo F., Raffaelli R., Memmo A. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J. Hypertens. 2010;28:135–142.
    1. Ahmed A.H., Gordon R.D., Taylor P.J. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J. Clin. Endocrinol. Metab. 2011;96:1797–1804.
    1. Ahmed A.H., Calvird M., Gordon R.D. Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J. Clin. Endocrinol. Metab. 2011;96:1039–1045. 2603.
    1. Ahmed A.H., Gordon R.D., Ward G. Effect of combined hormonal replacement therapy on the aldosterone/renin ratio in postmenopausal women. J. Clin. Endocrinol. Metab. 2017;102:2329–2334.
    1. Mulatero P., Rabbia F., Milan A. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40:897–902.
    1. Ahmed A.H., Gordon R.D., Taylor P. Effect of atenolol on aldosterone/renin ratio calculated by both plasma renin activity and direct renin concentration in healthy male volunteers. J. Clin. Endocrinol. Metab. 2010;95:3201–3206.
    1. Bello-Reuss E., Ernest S., Holland O.B., Hellmich M.R. Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am. J. Physiol. Cell Physiol. 2000;278:C1256–C1265.
    1. Rossi G.P. Primary aldosteronism: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019;74:2799–2811.
    1. Williams B., MacDonald T.M., Morant S. British Hypertension Society's PATHWAY Studies Group, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–2068.
    1. Bazoukis G., Thomopoulos C., Tsioufis C. Effect of MRAs on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. J. Hypertens. 2018;36:987–994.
    1. Nanba A.T., Wannachalee T., Shields J.J. Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism. J. Clin. Endocrinol. Metab. 2019;104:487–492.
    1. Haase M., Riester A., Kröpil P. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy. J. Clin. Endocrinol. Metab. 2014;99:4397–4402.
    1. Rossi G.P., Ceolotto G., Rossitto G. Effects of MIneralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism-EMIRA study. J. Clin. Endocrinol. Metab. 2020:dgaa080. Online ahead of print.
    1. Calhoun D.A., Jones D., Textor S. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American heart association professional education committee of the council for high blood pressure research. Hypertension. 2008;51:1403–1419.
    1. Maiolino G., Rossitto G., Bisogni V. Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: the Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) study. J. Am. Heart Assoc. 2017;6
    1. Rossi G.P., Bisogni V. A useful tool to improve the case detection rate of primary aldosteronism: the aldosterone -renin ratio (ARR)-App. J. Hypertens. 2016;34:1019–1021.
    1. Rossi G.P., Barisa M., Belfiore A. PAPY study Investigators, the aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J. Hypertens. 2010;28:1892–1899.
    1. Manolopoulou J., Fischer E., Dietz A. Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. J. Hypertens. 2015;33:2500–2511.
    1. Burrello J., Monticone S., Buffolo F. Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. J. Hypertens. 2016;34:920–927.
    1. Schirpenbach C., Seiler L., Maser-Gluth C. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin. Chem. 2006;52:1749–1755.
    1. Taylor P.J., Cooper D.P., Gordon R.D., Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin. Chem. 2009;55:1155–1162.
    1. Eisenhofer G., Dekkers T., Peitzsch M. Mass spectrometry – based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin. Chem. 2016;62:514–524.
    1. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am. J. Obstet. Gynecol. 2000;183:S1–S22.
    1. Riester A., Reincke M. Mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur. J. Endocrinol. 2015;172:R23–R30.
    1. Landau E., Amar L. Primary aldosteronism and pregnancy. Ann. Endocrinol. 2016;77:148–160. (Paris)
    1. Morton A. Primary aldosteronism and pregnancy. Pregnancy Hypertens. 2015;5:259–262.
    1. Fuller P.J., Yao Y.-Z., Jin R. Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonist. Proc. Natl. Acad. Sci. Unit. States Am. 2019;116:18578–18583.
    1. Cabassi A., Rocco R., Berretta R. Eplerenone use in primary aldosteronism during pregnancy. Hypertension. 2012;59:81–82.
    1. Streeten D.H., Tomycz N., Anderson G.H. Reliability of screening methods for the diagnosis of primary aldosteronism. Am. J. Med. 1979;67:403–413.
    1. Holland O.B., Brown H., Kuhnert L. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension. 1984;6:717–723.
    1. Weigel M., Riester A., Hanslik G. Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. Eur. J. Endocrinol. 2015;172:443–450.
    1. Song Y., Yang S., He W. Confirmatory tests for the diagnosis of primary aldosteronism. Hypertension. 2018;71:118–124.
    1. Cornu E., Steichen O., Nogueira-Silva L. Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism. Hypertension. 2016;68:989–994.
    1. Rossi G.P., Belfiore A., Bernini G. Primary Aldosteronism Prevalence in Italy Study Investigators, Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension. 2007;50:424–431.
    1. Bossuyt P.M., Reitsma J.B., Bruns D.E. Toward complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Am. J. Clin. Pathol. 2003;119:18–22.
    1. Rossi G.P., Seccia T.M., Pessina A.C. A diagnostic algorithm-the holy grail of primary aldosteronism. Nat. Rev. 2011;7:697–699.
    1. Young W.F., Stanson A.W., Thompson G.B. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136:1227–1235.
    1. Kempers M.J., Lenders J.W., van Outheusden L. Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann. Intern. Med. 2017;151:329–338.
    1. Lim V., Guo Q., Grant C.S. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J. Clin. Endocrinol. Metab. 2014;99:2712–2719.
    1. Ladurner R., Sommerey S., Buechner S. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur. J. Clin. Invest. 2017;47:372–377.
    1. Sam D., Kline G.A., So B., Leung A.A. Discordance between imaging and adrenal vein sampling in primary aldosteronism irrespective of interpretation criteria. J. Clin. Endocrinol. Metab. 2019;104:1900–1906.
    1. Aono D., Kometani M., Karashima S. Primary aldosteronism subtype discordance between computed tomography and adrenal venous sampling. Hypertens. Res. 2019;42:1942–1950.
    1. Rossi G.P., Mulatero P., Satoh F. 10 good reasons why adrenal vein sampling is the preferred method for referring primary aldosteronism patients for adrenalectomy. J. Hypertens. 2019;37:603–611.
    1. Rossi G.P., Barisa M., Allolio B. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J. Clin. Endocrinol. Metab. 2012;97:1606–1614.
    1. Almarzooqi M.K., Chagnon M., Soulez G. Adrenal vein sampling in primary aldosteronism: concordance of simultaneous vs sequential sampling. Eur. J. Endocrinol. 2017;176:159–167.
    1. Rossi G.P., Rossitto G., Amar L. The clinical outcomes of 1625 patients with primary aldosteronism subtyped with adrenal vein sampling. Hypertension. 2019;74:800–808.
    1. Rossitto G., Amar L., Azizi M. Subtyping of primary aldosteronism in the AVIS-2 Study: assessment of selectivity and lateralisation. J. Clin. Endocrinol. Metab. 2019:dgz017. Online ahead of print.
    1. Monticone S., Satoh F., Giacchetti G. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension. 2012;59:840–846.
    1. Wolley M.J., Ahmed A.H., Gordon R.D., Stowasser M. Does ACTH improve the diagnostic performance of adrenal vein sampling for subtyping primary aldosteronism? Clin. Endocrinol. 2016;85:703–709.
    1. Deinum J., Groenewoud H., Van Der Wilt G.J. Adrenal venous sampling: cosyntropin stimulation or not? Eur. J. Endocrinol. 2019;181:D15–D26.
    1. Wannachalee T., Zhao L., Nanba K. Three discrete patterns of primary aldosteronism lateralization in response to cosyntropin during adrenal vein sampling. J. Clin. Endocrinol. Metab. 2019;104:5867–5876.
    1. Rossitto G., Maiolino G., Lenzini L. Subtyping of primary aldosteronism with adrenal vein sampling: hormone- and side-specific effects of cosyntropin and metoclopramide. Surgery. 2018;163:789–795.
    1. Rossi G.P., Auchus R.J., Brown M. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63:151–160.
    1. Miotto D., De Toni R., Pitter G. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension. 2009;54:885–889.
    1. Ceolotto G., Antonelli G., Maiolino G. Androstenedione and 17-α-Hydroxyprogesterone are better indicators of adrenal vein sampling selectivity than cortisol. Hypertension. 2017;70:342–346.
    1. Dekkers T., Deinum J., Schultzekool L.J. Plasma metanephrine for assessing the selectivity of adrenal venous sampling. Hypertension. 2013;62:1152–1157.
    1. Hogan M.J., Schambelan M., Biglieri E.G. Concurrent hypercortisolism and hypermineralocorticoidism. Am. J. Med. 1977;62:777–782.
    1. Yoneda T., Karashima S., Kometani M. Impact of new quick gold nanoparticle-based cortisol assay during adrenal vein sampling for primary aldosteronism. J. Clin. Endocrinol. Metab. 2016;101:2554–2561.
    1. Georgiades C., Kharlip J., Valdeig S. Use of C-arm CT for improving the hit rate for selective blood sampling from adrenal veins. Radiologe. 2009;49:848–851.
    1. Makita K., Nishimoto K., Kiriyama-kitamoto K. A novel method: super-selective adrenal venous sampling. JoVE. 2017;2:55716.
    1. Dekkers T., Prejbisz A., Kool L.J.S. SPARTACUS Investigators, Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial. Lancet Diabetes Endocrinol. 2016;4:739–746.
    1. Young W.F. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J. Intern. Med. 2019;285:126–148.
    1. Williams T.A., Lenders J.W.M., Mulatero P. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;8587:1–11.
    1. Kupers E.M., Amar L., Raynaud A. A clinical prediction score to diagnose unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 2012;97:3530–3537.
    1. Sze W.C., Soh L.M., Lau J.H. Diagnosing unilateral primary aldosteronism – comparison of a clinical prediction score , computed tomography and adrenal venous sampling. Clin. Endocrinol. 2014;81:25–30.
    1. Riester A., Fischer E., Degenhart C. Quinkler, Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. J. Clin. Endocrinol. Metab. 2014;99:E1035–E1039.
    1. Lifton R.P., Dluhyt R.G., Powers M. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–265.
    1. Stowasser M., Gartside M.G., Gordon R.D. A PCR-based method of screening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Aust. N. Z. J. Med. 1997;27:685–690.
    1. Scholl U.I., Stölting G., Schewe J. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat. Genet. 2018;50:349–354.
    1. Choi M., Scholl U.I., Yue P. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–772.
    1. Monticone S., Buffolo F., Tetti M. The expanding genetic horizon of primary aldosteronism. Eur. J. Endocrinol. 2018;178:R101–R111.
    1. Scholl U.I., Stölting G., Nelson-Williams C. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4 e06315.
    1. Mulatero P., Tauber P., Zennaro M.C., Reincke M. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235–240.
    1. Prada E.T.A., Castellano I., Sušnik E. Comparative genomics and transcriptome profiling in primary aldosteronism. Int. J. Mol. Sci. 2018;19 pii: E1124.
    1. Omata K., Satoh F., Morimoto R., Ito S. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension. 2018;72:874–880.
    1. Meyer L.S., Wang X., Sušnik E. Immunohistopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism. Hypertension. 2018;72:650–657.
    1. Williams T.A., Peitzsch M., Dietz A.S. Genotype-specific steroid profiles associated with aldosterone-producing adenomas. Hypertension. 2016;67:139–145.
    1. Scholl U.I., Abriola L., Zhang C. Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma. J. Clin. Invest. 2017;127:2739–2750.
    1. Caroccia B., Prisco S., Seccia T.M. Macrolides blunt aldosterone biosynthesis: a proof-of-concept study in KCNJ5 mutated adenoma cells ex vivo. Hypertension. 2017;70:1238–1242.
    1. Maiolino G., Ceolotto G., Battistel M. vol. 27. Blood Press; 2018. pp. 200–205. (Macrolides for KCNJ5-Mutated Aldosterone-Producing Adenoma (MAPA): Design of a Study for Personalized Diagnosis of Primary Aldosteronism).
    1. Wolley M.J., Pimenta E., Calhoun D. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J. Hum. Hypertens. 2017;31:561–567.
    1. Florczak E., Prejbisz A., Szwench-Pietrasz E. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J. Hum. Hypertens. 2013;27:678–685.
    1. Buffolo F., Li Q., Monticone S. Primary aldosteronism and obstructive sleep apnea: a cross-sectional multi-ethnic study. Hypertension. 2019;74:1532–1540.
    1. Frasch H.F., Marshall C., Marshall B.E. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 1999;276:L304–L310.
    1. Belloni A.S., Rossi G.P., Andreis P.G. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 1996;27:1153–1159.
    1. Gonzaga C.C., Gaddam K.K., Ahmed M.I. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J. Clin. Sleep Med. 2010;6:363–368.
    1. Pimenta E., Stowasser M., Gordon R.D. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013;143:978–983.
    1. Wachtell K., Lehto M., Gerdts E. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End point reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol. 2005;45:712–719.
    1. Conen D., Tedrow U.B., Koplan B.A. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119:2146–2152.
    1. Erikssen G., Erikssen J., Arnesen H. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men. Hypertension. 2012;59:198–204.
    1. Okin P.M., Hille D.A., Larstorp A.C.K. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension. 2015;66:368–373.
    1. Kirchhof P., Benussi S., Kotecha D. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37:2893–2962.
    1. Bénitah J.P., Perrier E., Gómez A.M., Vassort G. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J. Physiol. 2001;537:151–160.
    1. Gómez A.M., Rueda A., Sainte-Marie Y. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation. 2009;119:2179–2187.
    1. Reil J.-C.C., Hohl M., Selejan S. Aldosterone promotes atrial fibrillation. Eur. Heart J. 2012;33:2098–2108.
    1. Milliez P., Girerd X., Plouin P.F. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005;45:1243–1248.
    1. Seccia T.M., Letizia C., Muiesan M.L. Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study. J. Hypertens. 2020;38:332–339.
    1. Rossi G.P., Maiolino G., Flego A. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension. 2018;71:585–591.
    1. Liu T., Korantzopoulos P., Shao Q. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. Europace. 2016;18:672–678.
    1. Neefs J., van den Berg N.W.E., Limpens J. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int. J. Cardiol. 2017;231:155–161.
    1. Swedberg K., Zannad F., McMurray J.J.V. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and SurvIval study in heart failure) study. J. Am. Coll. Cardiol. 2012;59:1598–1603.
    1. Hundemer G.L., Curhan G.C., Yozamp N. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3:768–774.
    1. Suzuki T., Abe H., Nagata S. Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. Am. J. Cardiol. 1988;62:1224–1227.
    1. Rossi G.P., Sacchetto A., Pavan E. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471–1478.
    1. Freel E.M., Mark P.B., Weir R.A. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging. 2012;5:740–747.
    1. Rossi G.P., Di Bello V., Ganzaroli C. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23–27.
    1. Tanabe A., Naruse M., Naruse K. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens. Res. 1997;20:85–90.
    1. Chang Y., Liao C., Tsai C. Left ventricular dysfunction in patients with primary aldosteronism: a propensity score–matching follow-up study with tissue Doppler imaging. J. Am. Heart Assoc. 2019;8
    1. Cesari M., Letizia C., Angeli P. Cardiac remodeling in patients with primary and secondary aldosteronism; A tissue Doppler study. Circ. Cardiovasc. Imaging. 2016;9:1–9.
    1. Erne P., Müller A., Rossi G.P. Aldosterone and renin in cardiac patients referred for catheterization. Medicine. 2017;96
    1. Monticone S., D'Ascenzo F., Moretti C. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41–50.
    1. Frustaci A., Letizia C., Verardo R. Primary aldosteronism-associated cardiomyopathy: clinical-pathologic impact of aldosterone normalization. Int. J. Cardiol. 2019;292:141–147.
    1. Indra T., Holaj R., Štrauch B. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J. Renin-Angiotensin-Aldosterone Syst. JRAAS. 2015;16:1109–1117.
    1. Catena C., Colussi G., Lapenna R. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911–918.
    1. Lin Y.H., Wu X.M., Lee H.H. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J. Hypertens. 2012;30:1606–1613.
    1. Hundemer G.L., Curhan G.C., Yozamp N. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72:658–666.
    1. Monticone S., Sconfienza E., D'Ascenzo F. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J. Hypertens. 2020;38:3–12.
    1. Hundemer G.L., Curhan G.C., Yozamp N. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–59.
    1. Halimi J.M., Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J. Hypertens. 1995;13:1801–1802.
    1. Rossi G.P., Bernini G., Desideri G. PAPY Study Participants, Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232–238.
    1. Satoh M., Maruhashi T., Yoshida Y., Shibata H. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. Hypertens. Res. 2019;42:817–824.
    1. Rossi G.P. Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage. Hypertens. Res. 2011;34:286–288.
    1. Gao X., Yamazaki Y., Tezuka Y. The crosstalk between aldosterone and calcium metabolism in primary aldosteronism: a possible calcium metabolism-associated aberrant “neoplastic” steroidogenesis in adrenals. J. Steroid Biochem. Mol. Biol. 2019;193
    1. Wu V.C., Chang C.H., Wang C.Y. Risk of fracture in primary aldosteronism: a population-based cohort study. J. Bone Miner. Res. 2017;32:743–752.
    1. Notsu M., Yamauchi M., Yamamoto M. Primary aldosteronismas a risk factor for vertebral fracture. J. Clin. Endocrinol. Metab. 2017;102:1237–1243.
    1. Kim B.J., Kwak M.K., Ahn S.H. Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by aldosterone excess. J. Clin. Endocrinol. Metab. 2018;103:615–621.
    1. Pilz S., Kienreich K., Drechsler C. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J. Clin. Endocrinol. Metab. 2011;97:E75–E79.
    1. Rossi G.P., Ragazzo F., Seccia T.M. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension. 2012;60:431–436.
    1. Maniero C., Fassina A., Seccia T.M. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J. Hypertens. 2012;30:390–395.
    1. Salcuni A.S., Palmieri S., Carnevale V. Bone involvement in aldosteronism. J. Bone Miner. Res. 2012;27:2217–2222.
    1. Salcuni A.S., Carnevale V., Battista C. Primary aldosteronism as a cause of secondary osteoporosis. Eur. J. Endocrinol. 2017;177:431–437.
    1. Ceccoli L., Ronconi V., Giovannini L. Bone health and aldosterone excess. Osteoporos. Int. 2013;24:2801–2807.
    1. Muth A., Ragnarsson O., Johannsson G., Wängberg B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br. J. Surg. 2015;102:307–317.
    1. Zhou Y., Zhang M., Ke S., Liu L. Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis. BMC Endocr. Disord. 2017;17:61.
    1. Calhoun D.A. Medical versus surgical treatment of primary aldosteronism. Hypertension. 2018;71:566–568.
    1. Wu V.C., Wang S.M., Chang C.H. Long term outcome of Aldosteronism after target treatments. Sci. Rep. 2016;6:32103.
    1. Reincke M., Fischer E., Gerum S. German Conn's Registry-Else Kröner-Fresenius-Hyperaldosteronism Registry, Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension. 2012;60:618–624.
    1. Catena C., Colussi G., Nadalini E. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 2008;168:80–85.
    1. Giacchetti G., Ronconi V., Turchi F. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 2007;25:177–186.
    1. Sukor N., Kogovsek C., Gordon R.D. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 2010;95:1360–1364.
    1. Citton M., Viel G., Rossi G.P. Outcome of surgical treatment of primary aldosteronism. Langenbeck's Arch. Surg. 2015;400:325–331.
    1. Iacobone M., Citton M., Viel G. Approach to the surgical management of primary aldosteronism. Gland Surg. 2015;4:69–81.
    1. Walz M.K., Gwosdz R., Levin S.L. Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia. World J. Surg. 2008;32:847–853.
    1. Utsumi T., Kawamura K., Imamoto T. High predictive accuracy of Aldosteronoma Resolution Score in Japanese patients with aldosterone-producing adenoma. Surgery. 2012;151:437–443.
    1. Iwakura Y., Morimoto R., Kudo M. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J. Clin. Endocrinol. Metab. 2014;99:1593–1598.
    1. Brunt L.M. Minimal access adrenal surgery. Surg. Endosc. Other Interv. Tech. 2006;20:351–361.
    1. Chen W., Li F., Chen D. Retroperitoneal versus transperitoneal laparoscopic adrenalectomy in adrenal tumor: a meta-analysis. Surg. Laparosc. Endosc. Percutaneous Tech. 2013;23:121–127.
    1. Conzo G., Tartaglia E., Gambardella C. Minimally invasive approach for adrenal lesions: systematic review of laparoscopic versus retroperitoneoscopic adrenalectomy and assessment of risk factors for complications. Int. J. Surg. 2016;28:S118–S123.
    1. Nigri G., Rosman A.S., Petrucciani N. Meta-analysis of trials comparing laparoscopic transperitoneal and retroperitoneal adrenalectomy. Surgery. 2013;153:111–119.
    1. Constantinides V.A., Christakis I., Touska P., Palazzo F.F. Systematic review and meta-analysis of retroperitoneoscopic versus laparoscopic adrenalectomy. Br. J. Surg. 2012;99:1639–1648.
    1. Pahwa M. Robot-assisted adrenalectomy: current perspectives. Robot Surg. 2017;4:1–6.
    1. Simone G., Anceschi U., Tuderti G. Robot-assisted partial adrenalectomy for the treatment of conn's syndrome: surgical technique, and perioperative and functional outcomes. Eur. Urol. 2019;75:811–816.
    1. Nehs M.A., Ruan D.T. Minimally invasive adrenal surgery: an update. Curr. Opin. Endocrinol. Diabetes Obes. 2011;18:193–197.
    1. Nishikawa T., Matsuzawa Y., Saito J., Omura M. Is it possible to extirpate cardiovascular events in primary aldosteronism after surgical treatment, Japanese. Clin. Med. 2010;1:21–23.
    1. Liu S.Y., Ng E.K., Lee P.S. Radiofrequency ablation for benign aldosterone-producing adenoma: a scarless technique to an old disease. Ann. Surg. 2010;252:1058–1064.
    1. Uppot R.N., Gervais D.A. Imaging-guided adrenal tumor ablation. AJR Am. J. Roentgenol. 2013;200:1226–1233.
    1. Yamakado K. Image-guided ablation of adrenal lesions. Semin. Intervent. Radiol. 2014;31:149–156.
    1. Yang M.H., Tyan Y.S., Huang Y.H. Comparison of radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing adenoma. Radiol. Medica. 2016;121:811–819.
    1. Yang R., Xu L., Lian H. Retroperitoneoscopic-guided cool-tip radiofrequency ablation of adrenocortical aldosteronoma. J. Endourol. 2014;28:1208–1214.
    1. Hokotate H., Inoue H., Baba Y. Aldosteronomas: experience with superselective adrenal arterial embolization in 33 cases. Radiology. 2003;227:401–406.
    1. Steichen O., Amar L., Chaffanjon P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: adrenal surgery. Ann. Endocrinol. 2016;77:220–225. (Paris)
    1. Shariq O.A., Bancos I., Cronin P.A. Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism. Surgery. 2018;163:183–190.
    1. Wada N., Shibayama Y., Umakoshi H. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism. J. Hum. Hypertens. 2017;31:627–632.
    1. Starker L.F., Christakis I., Julien J.S. Considering postoperative functional hypoaldosteronism after unilateral adrenalectomy. Am. Surg. 2017;83:598–604.
    1. Proye C.A., Mulliez E.A., Carnaille B.M. Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery. 1998;124:1128–1133.
    1. Zarnegar R., Young W.F., Lee J. The aldosteronoma resolution score predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann. Surg. 2008;247:511–518.
    1. Vriens M.R., Vorselaars W.M.C.M., Nell S. Clinical outcomes after unilateral adrenalectomy for primary aldosteronism. JAMA Surg. 2019;154 e185842.
    1. Lim P.O., Jung R.T., MacDonald T.M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br. J. Clin. Pharmacol. 1999;48:756–760.
    1. Sechi L., Colussi G., Novello M. Mineralocorticoid receptor antagonists and clinical outcomes in primary aldosteronism: as good as surgery? Horm. Metab. Res. 2015;47:1000–1006.
    1. Doumas M., Boutari C., Tsioufis C. Clinical value of measuring the renin/aldosterone levels: optimising the management of uncontrolled/resistant hypertension. Curr. Vasc. Pharmacol. 2017;16:10–14.
    1. Lainscak M., Pelliccia F., Rosano G. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int. J. Cardiol. 2015;200:25–29.
    1. Capelli I., Gasperoni L., Ruggeri M. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J. Nephrol. 2020;33:37–48.
    1. Amar L., Azizi M., Menard J. Aldosterone synthase inhibition with LCI699. Hypertension. 2010;56:831–838.
    1. Mattsson C., Young W.F. Primary aldosteronism: diagnostic and treatment strategies. Nat. Clin. Pract. 2006;2:198–208.
    1. Young W.F. Minireview: primary aldosteronism- changing concepts in diagnosis and treatment. Endocrinology. 2003;144:2208–2213.
    1. Rossi G.P., Vendraminelli R., Cesari M., Pessina A.C. A thoracic mass with hypertension and hypokalaemia. Lancet. 2000;356:1570.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner